Published in Brain on March 12, 2014
Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. Brain (2016) 1.51
microRNA-34a-Mediated Down-Regulation of the Microglial-Enriched Triggering Receptor and Phagocytosis-Sensor TREM2 in Age-Related Macular Degeneration. PLoS One (2016) 1.46
The low-density lipoprotein receptor-related protein 1 and amyloid-β clearance in Alzheimer's disease. Front Aging Neurosci (2014) 1.01
Detection of subjects and brain regions related to Alzheimer's disease using 3D MRI scans based on eigenbrain and machine learning. Front Comput Neurosci (2015) 0.92
Alzheimer's disease: experimental models and reality. Acta Neuropathol (2016) 0.88
Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. Acta Neuropathol Commun (2015) 0.87
Genetic heterogeneity in Alzheimer disease and implications for treatment strategies. Curr Neurol Neurosci Rep (2014) 0.82
Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer's disease. Acta Neuropathol (2016) 0.81
Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain. Acta Neuropathol Commun (2016) 0.80
Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability. Alzheimers Dement (2016) 0.78
APOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations. Ann Neurol (2016) 0.77
Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. J Neuropathol Exp Neurol (2016) 0.77
Impairment of the nerve growth factor pathway driving amyloid accumulation in cholinergic neurons: the incipit of the Alzheimer's disease story? Neural Regen Res (2016) 0.76
Astrocytic LRP1 Mediates Brain Aβ Clearance and Impacts Amyloid Deposition. J Neurosci (2017) 0.75
Maternal dexamethasone exposure ameliorates cognition and tau pathology in the offspring of triple transgenic AD mice. Mol Psychiatry (2015) 0.75
Identification of plexin A4 as a novel clusterin receptor links two Alzheimer's disease risk genes. Hum Mol Genet (2016) 0.75
An antioxidant specifically targeting mitochondria delays progression of Alzheimer's disease-like pathology. Aging (Albany NY) (2016) 0.75
Angiotensin-converting enzyme insertion/deletion polymorphism is not a major determining factor in the development of sporadic Alzheimer disease: evidence from an updated meta-analysis. PLoS One (2014) 0.75
Chronic low-dose-rate ionising radiation affects the hippocampal phosphoproteome in the ApoE-/- Alzheimer's mouse model. Oncotarget (2016) 0.75
Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle. NPJ Aging Mech Dis (2015) 0.75
Familial Alzheimer's Disease Lymphocytes Respond Differently Than Sporadic Cells to Oxidative Stress: Upregulated p53-p21 Signaling Linked with Presenilin 1 Mutants. Mol Neurobiol (2016) 0.75
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci (2005) 12.85
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology (2002) 7.73
Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70
APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet (2005) 7.66
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron (2005) 7.53
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature (1992) 6.51
Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron (1994) 6.41
Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature (1996) 5.50
Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci (2011) 5.40
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 4.86
Amyloid precursor protein trafficking, processing, and function. J Biol Chem (2008) 4.79
2013 Alzheimer's disease facts and figures. Alzheimers Dement (2013) 4.75
Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res (1991) 4.31
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov (2011) 4.24
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci (2009) 3.97
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A (2009) 3.86
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol (2002) 3.23
Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron (2008) 3.08
Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging (1992) 3.05
Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ ) deposition. Proc Natl Acad Sci U S A (2010) 2.80
Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med (2004) 2.72
Tau pathology and neurodegeneration. Lancet Neurol (2013) 2.66
Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat (2006) 2.29
Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol (2000) 2.21
Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease. Brain (2013) 2.05
Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol (2005) 1.94
Phenotype associated with APP duplication in five families. Brain (2006) 1.83
Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J (2009) 1.73
Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent β-amyloid generation. Cell (2011) 1.52
High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol (2009) 1.45
PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain (2008) 1.34
Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol (2008) 1.31
Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol (1996) 1.24
Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42. Neurobiol Aging (2005) 1.20
Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain (2010) 1.17
Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol (2012) 1.14
Genotype-phenotype relationships of presenilin-1 mutations in Alzheimer's disease: an update. J Alzheimers Dis (2009) 1.10
Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Neurosci Lett (1997) 1.08
Differential incorporation of tau isoforms in Alzheimer's disease. J Alzheimers Dis (2008) 1.04
Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation. Neurosci Lett (2010) 1.00
Localization of amyloid precursor protein in selective postsynaptic densities of rat cortical neurons. Brain Res (1992) 0.99
Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease. Nat Med (2004) 0.98
Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimer's disease mutations. J Neurol Neurosurg Psychiatry (2012) 0.97
Brain regional correlation of amyloid-β with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-β accumulation. Acta Neuropathol (2013) 0.96
Presence of apolipoprotein E on extracellular neurofibrillary tangles and on meningeal blood vessels precedes the Alzheimer beta-amyloid deposition. Acta Neuropathol (1994) 0.91
Alzheimer's disease families with amyloid precursor protein mutations. Ann N Y Acad Sci (1993) 0.89
Caudate infarcts and hemorrhages. Front Neurol Neurosci (2012) 0.87
A quantitative and immunohistochemical study on apolipoprotein E in brain tissue in Alzheimer's disease. Dement Geriatr Cogn Disord (2000) 0.85
Brain regions and genes affecting myoclonus in animals. Neurosci Res (2012) 0.83
Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism Relat Disord (2004) 0.83
Distribution of apolipoprotein E in senile plaques in brains with Alzheimer's disease: investigation with the confocal laser scan microscope. Brain Res (1997) 0.81
Seizures and the basal ganglia: a review of the clinical data. Epileptic Disord (2002) 0.80
Immunohistochemical detection of apolipoprotein E within prion-associated lesions in squirrel monkey brains. Acta Neuropathol (2000) 0.79
Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease. Neuropathol Appl Neurobiol (1997) 0.79
Pick's disease: selective occurrence of apolipoprotein E-immunoreactive Pick bodies in the limbic system. Acta Neuropathol (1998) 0.76
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (2006) 11.59
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Mild cognitive impairment. Lancet (2006) 10.21
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature (2006) 9.31
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
novoSNP, a novel computational tool for sequence variation discovery. Genome Res (2005) 7.42
The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 6.85
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol (2007) 5.98
The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology (2008) 5.94
Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron (2013) 5.91
TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol (2008) 5.58
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord (2009) 5.50
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA (2011) 5.21
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol (2006) 4.91
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet (2006) 4.80
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med (2009) 4.45
Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage (2007) 4.41
A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain (2009) 4.40
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol (2013) 4.16
Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain (2006) 4.07
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature (2013) 4.03
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet (2009) 4.00
Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med (2005) 4.00
Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron (2008) 3.98
TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol (2010) 3.92
DCTN1 mutations in Perry syndrome. Nat Genet (2009) 3.87
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry (2010) 3.66
Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2009) 3.65
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol (2011) 3.63